Provided by Tiger Trade Technology Pte. Ltd.

Rallybio Corp.

4.33
-0.4900-10.17%
Volume:174.41K
Turnover:760.90K
Market Cap:22.86M
PE:-1.71
High:4.93
Open:4.74
Low:3.67
Close:4.82
52wk High:6.75
52wk Low:1.76
Shares:5.28M
Float Shares:2.54M
Volume Ratio:11.48
T/O Rate:6.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5283
EPS(LYR):-10.6143
ROE:-21.17%
ROA:-28.35%
PB:0.36
PE(LYR):-0.41

Loading ...

Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Benzinga
·
Yesterday

BRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 Study

Reuters
·
Yesterday

Rallybio Reports Positive Phase 1 Results for RLYB116 in Complement-Mediated Diseases

Reuters
·
Yesterday

Rallybio Corp - Rlyb116 Phase 2 Trial Planned for 2H 2026 With Potential for Topline Data in 2027

THOMSON REUTERS
·
Yesterday

Rallybio Announces Positive Data for Rlyb116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

THOMSON REUTERS
·
Yesterday

Rallybio Corp - Rlyb116 Doses Well Tolerated With No Gi Side Effects

THOMSON REUTERS
·
Yesterday

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM

Reuters
·
Feb 06

Rallybio Corp trading halted, news pending

TIPRANKS
·
Feb 06

BRIEF-Rallybio Announces Reverse Stock Split Of Common Stock

Reuters
·
Feb 04

Rallybio führt Aktiensplit im Verhältnis 1:8 durch

Reuters
·
Feb 04

Rallybio Corp - to Effect One-for-Eight Reverse Stock Split

THOMSON REUTERS
·
Feb 04

Rallybio Shareholders Approve Reverse Stock Split Amendment

TIPRANKS
·
Jan 30

Rallybio Corporation Held Special Shareholder Meeting

Reuters
·
Jan 30

Rallybio Terminates Phase 2 FNAIT Pregnancy Study: What Investors Need to Know

TIPRANKS
·
Jan 14

Rallybio’s Phase 2 FNAIT Prevention Study Reaches Completion: What Investors Should Watch Next

TIPRANKS
·
Jan 10

Rallybio Corporation Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Dec 24, 2025

Rallybio Corporation Reports Strong Q3 2025 Results

TIPRANKS
·
Nov 07, 2025

UPDATE: Rallybio Q3 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate

Benzinga
·
Nov 06, 2025

Rallybio posts Q3 net income of $16 million

Reuters
·
Nov 06, 2025

BRIEF-Rallybio Q3 Net Income USD 16.016 Million

Reuters
·
Nov 06, 2025